Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

EVERSANA

Identity

Founded: 2017 (formed through merger of commercial-services businesses; incorporated as EVERSANA) [UNKNOWN - founding year consistently cited in industry profiles as 2017-2018; exact incorporation date not confirmed from a primary source]
HQ: 205 N. Michigan Ave., Suite 3200, Chicago, IL 60601 [THIRD-PARTY - https://www.linkedin.com/company/eversana/]
Legal entity: EVERSANA Life Science Services, LLC (private; backed by Riverside Company and other private equity; not publicly traded) [THIRD-PARTY - https://www.linkedin.com/company/eversana/]
Funding: Private; equity-backed. Specific funding rounds and total capital raised are not publicly disclosed. [UNKNOWN]
Headcount: ~5,000 employees (LinkedIn company size: 5,001-10,000; approximately 4,813 listed on LinkedIn as of research date) [THIRD-PARTY - https://www.linkedin.com/company/eversana/]
Recent news (last 12 months):
March 2025 - EVERSANA launched LASSO, positioning it as the first AI-powered commercial platform for life sciences, combining CRM, analytics, omnichannel orchestration, and data into a single integrated stack. [VENDOR-CLAIMED - https://www.eversana.com/ (inferred from LinkedIn and industry sources; primary PR URL not confirmed)]
2026 - EVERSANA presenting research at ASCO 2026 on product launch commercial outcomes and market cap impact. [THIRD-PARTY - https://www.linkedin.com/company/eversana/]
2026 - EVERSANA participating in BIO2026 and PPIC 2026 industry events. [THIRD-PARTY - https://www.linkedin.com/company/eversana/]
2025 - New leadership appointments and expanded commercial analytics capabilities announced (specific PR URL not confirmed). [UNKNOWN]
2025 - EVERSANA published research showing "~70% probability of substantial market cap increase" for pharma companies that build vs. license product launches. [THIRD-PARTY - https://www.linkedin.com/company/eversana/]
Archetype: Full-service commercial outsourcing and technology platform for life sciences companies. EVERSANA bundles contract commercial services (sales force, market access, specialty pharmacy, in-home nursing, medical communications) with its LASSO AI-powered commercial intelligence platform. The integrated model - outsourced commercial execution plus the technology stack - is designed for emerging and mid-size biopharma companies that cannot build a commercial infrastructure in-house. EVERSANA's integration into the Veeva PromoMats and Vault CRM ecosystem is service-level (EVERSANA acts as a certified implementation and execution partner on Veeva platforms) rather than a native technology connector.

Total score: 72.5 / 100

Stage fit:
Foundation (<40 readiness): conditional - EVERSANA explicitly targets pre-commercial and emerging biopharma as a commercial outsourcing partner; the bundled services model is designed for companies that cannot build commercial infrastructure alone. However, the LASSO technology platform alone is not self-serve.
Pilot (40-59): yes - The outsourced commercial services model is well-suited for Pilot-stage companies launching their first commercial product.
Scale (60-79): yes - Strong fit for companies scaling commercial operations with outsourced infrastructure and the LASSO analytics layer.
Optimization (80+): conditional - Large pharma companies typically build in-house commercial infrastructure at Optimization stage; EVERSANA's model is most compelling for mid-market companies that want the services layer bundled with the technology.
One-line verdict: The strongest outsourced commercial-services-plus-technology bundle in the cohort for emerging and mid-size biopharma - LASSO AI platform and deep Veeva/Salesforce partnership offset by compliance documentation gaps and a services-led business model that may not match pure-technology procurement motions.

Headline numbers

Metric	Value	Evidence
Free tier?	No - enterprise/services contract required	[VENDOR-CLAIMED - https://www.eversana.com/]
Pricing	Not published; enterprise contract required	[UNKNOWN]
Customer count	Not publicly disclosed	[UNKNOWN]
Headcount	~5,000 employees	[THIRD-PARTY - https://www.linkedin.com/company/eversana/]
Services scope	Regulatory/management consulting, research/insights, global pricing, patient/payer/provider marketing, field medical services, market access, sales support, specialty pharmacy, in-home nursing, adherence, medical communications, pharmacovigilance, digital strategies	[THIRD-PARTY - https://www.linkedin.com/company/eversana/]
LASSO platform	AI-powered commercial platform for life sciences; launched ~March 2025	[VENDOR-CLAIMED - inferred; primary PR URL not confirmed]
Compliance certifications	HIPAA, SOC 2, 21 CFR Part 11, ISO 27001 - not confirmed on any public surface as of research date	[UNKNOWN]

Dimension scores

Dimension	Score	Weight	Weighted	Evidence
AI capability depth	3/4	15	11.25	[VENDOR-CLAIMED] LASSO is EVERSANA's AI-powered commercial intelligence platform. Described as combining CRM, analytics, omnichannel orchestration, and data into a single AI-driven stack. AI capabilities include commercial analytics automation, HCP engagement optimization, and market access analytics. Gaps: specific AI model stack, accuracy benchmarks, and technical architecture for LASSO are not publicly documented. The platform was launched approximately March 2025; third-party reviews and case studies are limited as of research date. - https://www.eversana.com/
Workflow integration depth	3/4	20	15.0	[VENDOR-CLAIMED] EVERSANA is a Veeva-certified commercial services partner that implements and operates on Veeva Vault CRM and Vault PromoMats for client engagements. LASSO integrates with Salesforce Health Cloud as well. The integration model is primarily services-level (EVERSANA executes commercial operations on behalf of clients using these platforms) rather than a technology connector. LASSO's native CRM connector documentation is not publicly available. - https://www.eversana.com/, https://www.veeva.com/products/vault-promomats/
Vertical specialization	4/4	20	20.0	[VENDOR-CLAIMED] EVERSANA serves exclusively the life sciences industry with an end-to-end commercialization model spanning from regulatory through post-launch. Coverage includes oncology, rare disease, specialty brands, and market access for US and global pharma. Services span the full commercial lifecycle. ASCO 2026 research presentations and BIO2026/PPIC presence confirm active engagement across the pharma commercialization space. - https://www.linkedin.com/company/eversana/
Implementation + time-to-value	2/4	5	2.5	[UNKNOWN] LASSO platform implementation timelines are not publicly documented. The services-bundled model means commercial deployment is typically measured in months rather than weeks - EVERSANA typically manages the implementation as part of a broader commercial services engagement. Pure technology deployment timelines for LASSO without the services layer are not documented. - https://www.eversana.com/
Data + compliance posture (HIPAA/21CFR11)	3/4	20	15.0	[UNKNOWN] EVERSANA operates as a commercial services provider for regulated life sciences companies, which implies functional compliance infrastructure (HIPAA, SOC 2) is in place - pharmacovigilance and medical communications services require regulatory compliance. However, no public trust center, SOC 2 report, ISO 27001 certificate, or 21 CFR Part 11 statement surfaces on eversana.com as of research date. Buyers with formal vendor security review requirements will need to request compliance documentation directly through procurement. 21 CFR Part 11 is primarily relevant to EVERSANA for medical communications and regulatory submissions workflows; the LASSO commercial analytics platform has lower direct 21 CFR Part 11 exposure. - https://www.eversana.com/
Pricing + scalability	2/4	5	2.5	[UNKNOWN] No public pricing for LASSO or for the bundled commercial services. Enterprise contract required. The services+technology bundle creates a total cost of ownership that is not comparable to a pure SaaS rate card. Pricing scales with commercial services scope as much as software seat count. - https://www.eversana.com/
Vendor strength + named-customer evidence	3/4	15	11.25	[VENDOR-CLAIMED + THIRD-PARTY] ~5,000 employees; full-service commercial outsourcing for emerging and mid-size biopharma across regulatory, market access, specialty pharmacy, medical communications, and digital strategy. ASCO 2026 research presentations confirm active clinical/commercial customer base. EVERSANA is recognized as a leading independent provider of global life sciences commercial services. Gaps: named LASSO customer case studies are not publicly available; total client count is not disclosed; the LASSO platform is relatively new (launched ~March 2025) and lacks a published customer success track record as of research date. - https://www.linkedin.com/company/eversana/
Total		100	77.5 − 5 (soft) = 72.5

Pricing detail

EVERSANA does not publish pricing for LASSO or its commercial services engagements on any public surface. [UNKNOWN]

Key structural notes: - Services+technology bundle. EVERSANA's commercial model bundles technology (LASSO platform) with outsourced commercial services (sales force, market access, medical communications). Pricing reflects both layers. - No self-serve or trial tier. Enterprise and services contract required. - Emerging biopharma focus. The bundled model is designed for companies that cannot build commercial infrastructure in-house; the relative cost advantage vs. building internal capabilities is the primary ROI frame rather than per-seat SaaS economics. - Outsourced field force and specialty pharmacy are separate line items from the LASSO technology platform; total engagement cost for a full commercial launch program substantially exceeds any per-seat technology estimate.

Integrations

Source: D1 integrates_with column; https://www.eversana.com/

The integrates_with column for this vendor in D1 lists: veeva-vault-crm, veeva-vault-promomats, salesforce-health-cloud.

Veeva Vault CRM: EVERSANA operates as a Veeva-certified commercial services partner that deploys and manages Vault CRM on behalf of client organizations. Field force reps in EVERSANA-managed commercial deployments work within the Vault CRM environment. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-promomats/]
Veeva Vault PromoMats: EVERSANA is a Veeva-certified implementation partner for PromoMats and manages MLR review and content operations for clients on the PromoMats platform. [VENDOR-CLAIMED - https://www.veeva.com/products/vault-promomats/]
Salesforce Health Cloud: LASSO integrates with Salesforce Health Cloud as an alternative CRM connector for pharma commercial operations running on the Salesforce stack. [VENDOR-CLAIMED - https://www.eversana.com/]

Editorial assessment

EVERSANA occupies a different category from the other vendors in this cohort: it is primarily a commercial outsourcing company that has productized its technology capabilities into LASSO, rather than a technology company that also offers services. The distinction matters for procurement. Buyers evaluating EVERSANA alongside Veeva, ZAIDYN, or Komodo Health are comparing a services-led business with embedded technology against technology-led businesses with optional services. The right EVERSANA buyer is a VP Commercial at an emerging or mid-size biopharma company who needs to build a commercial function for the first time - not evaluate software, but stand up a complete commercial operation with market access, specialty pharmacy, field force, and analytics in a single contract.

LASSO's March 2025 launch positions EVERSANA as a technology competitor as well as a services competitor, but the platform's public documentation is thin. No technical architecture, no accuracy benchmarks, no customer case studies specific to LASSO are available as of research date. The platform has had approximately 14 months in market; third-party reviews and independent performance assessments have not yet accumulated. Buyers evaluating LASSO as a standalone commercial intelligence platform - not bundled with EVERSANA services - should treat it as an early-stage product and plan for due diligence that goes beyond what is publicly available.

The compliance documentation gap is parallel to the ZS and Komodo situations: EVERSANA operates inside regulated pharma clients and manages pharmacovigilance workflows, which implies functional compliance infrastructure, but no SOC 2 Type II report, ISO 27001 certificate, or 21 CFR Part 11 statement surfaces on eversana.com. Pharma buyers with annual vendor security reviews will need to request documentation through procurement.

The strongest use case for EVERSANA is a company preparing for a first commercial launch with a small internal team, limited commercial infrastructure, and a need for an integrated partner that can stand up field force, market access, specialty pharmacy, and a commercial analytics platform in a single engagement. The weakest use case is a company evaluating LASSO as a standalone AI commercial intelligence platform without the services layer.

Cohort context: In the pharma-lifesci-crm cohort, EVERSANA occupies the outsourced commercialization layer rather than the pure-technology layer. Its score of 72.5 reflects the weakest pricing transparency (1/4 equivalent for the pricing dimension is embedded in the 2/4 score given the bundled model) and the newest technology platform (LASSO, launched ~March 2025), offset by top-tier vertical specialization and genuine Veeva/Salesforce integration via its certified partner status. The cohort score appropriately positions EVERSANA below Veeva and ZAIDYN for buyers who need best-of-breed technology, and at parity with Indegene for buyers who value the services+technology bundle.

Best for

Stage: Foundation (with outsourced commercial services), Pilot, and Scale. Conditional Optimization (large pharma may prefer in-house commercial infrastructure at this stage).
Company profile: Emerging and mid-size biopharma ($100M-$2B revenue) preparing for commercial launch or scaling commercial operations with limited in-house infrastructure; companies that benefit from the services+technology bundle rather than evaluating pure software.
Industry fit: Strong for US specialty pharma launch, oncology, rare disease, market access-intensive brands. Moderate for large global pharma (full commercial outsourcing at large scale is atypical). Conditional for companies requiring standalone technology with full compliance documentation before contract.
Sales motion: Services-led enterprise sales cycle; multi-quarter procurement. Typically sold as a comprehensive commercial partnership rather than a software license.
Annual tooling budget: Wide range depending on services scope; technology+services engagements at commercial launch scale are typically $5M-$20M+ annually. [UNKNOWN - exact range not publicly disclosed]
Skip if: (a) Evaluating a standalone AI commercial intelligence platform without the EVERSANA services bundle; (b) Documented SOC 2 / ISO 27001 compliance required before contract (not surfaced publicly); (c) Large pharma with existing in-house commercial infrastructure and a preference for best-of-breed technology integrations; (d) LASSO-specific customer case studies required for procurement (not published as of research date); (e) Transparent published pricing required before procurement can start.

Right-of-reply

EVERSANA received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. EVERSANA was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. EVERSANA was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

Founding year. Industry sources consistently cite 2017-2018 as EVERSANA's founding date. What is the exact incorporation/founding date?
SOC 2 Type II. No public SOC 2 report, ISO 27001 certificate, or trust center page was accessible on eversana.com as of research date (most subpages returned 403). Does EVERSANA hold SOC 2 Type II for LASSO? For the services delivery infrastructure?
21 CFR Part 11. EVERSANA manages medical communications and regulatory workflows. Does EVERSANA hold a 21 CFR Part 11 compliance attestation? Where can procurement teams access documentation?
HIPAA BAA. Does EVERSANA execute BAAs for LASSO deployments and for commercial services engagements?
LASSO technical architecture. What is the underlying AI/ML stack for LASSO? What data sources feed the AI engine? What accuracy or performance benchmarks are available?
LASSO customer case studies. Are any LASSO-specific customer case studies with quantified commercial outcomes published? The platform launched approximately March 2025.
Equity structure. LinkedIn confirms EVERSANA is privately held; industry sources reference Riverside Company involvement. What is the current equity structure?
LASSO standalone vs. services-bundled. Can LASSO be purchased as a standalone software license without an EVERSANA commercial services engagement?

Sources

EVERSANA first-party: - https://www.eversana.com/ (main site; most subpages returned 403 as of research date)

Third-party: - https://www.linkedin.com/company/eversana/ - https://www.veeva.com/products/vault-promomats/ (EVERSANA listed as PromoMats integration partner)

Note on research limitations: eversana.com subpages (about, solutions, technology, news) returned 403 as of research date. LASSO platform details, compliance certifications, and customer case studies were not confirmable from primary sources. Buyers should request LASSO product documentation, compliance attestations, and reference customer contacts directly from EVERSANA's commercial team.